Fairmount Funds Management LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802528

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth Tilt how tags are computed

Q2 2026 · 12 positions · Total reported value $1.51B · Top-10 concentration 97.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 15.4% · 1 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.7% · vs SPY +16.9% · Prev Value $1.38B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Fairmount Funds Management LLC disclosed 12 equity positions with a combined reported value of $1.51B. The filing implies a focused portfolio: its ten largest positions account for 97.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were ORKA ($352.63M), DNTH ($247.33M), DMRA ($226.63M). By sector, the heaviest allocations are Health Care 96.2%, Other 3.8%. Versus the prior quarter, allocation shifted toward Other (+2.0pp) and away from Health Care (-2.0pp).

Versus the prior quarter, Fairmount Funds Management LLC opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 15.4% of positions. The portfolio's overlap with the prior quarter was 85% of names.

The largest new positions opened in Q2 2026 were FTH ($18.05M).

Of the 1 positions fully exited versus the prior quarter, the largest were SYRE ($202.67M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • FTH FAETH THERAPEUTICS INC · $18.05M

Fully Exited (vs previous quarter)

  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $202.67M

Insider Transactions (Form 4)

Latest Fairmount Funds Management LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-09-03 D Apogee Therapeutics, Inc. 51,166 — SEC filing
2026-09-03 D Apogee Therapeutics, Inc. 340,855 — SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 10,370 $43.85 SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 31,838 $17.00 SEC filing
2026-07-16 Buy CRESCENT BIOPHARMA, INC. 853,450 $14.50 SEC filing
2026-07-01 Sell Oruka Therapeutics, Inc. 3,553,410 $84.43 SEC filing
2026-07-01 Conversion Oruka Therapeutics, Inc. 3,553,410 — SEC filing
2026-06-23 Sell Spyre Therapeutics, Inc. 4,684,781 $85.31 SEC filing

All insider transactions →

Fund Profile

Fairmount Funds Management LLC, based in West Conshohocken, PA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 12 positions worth $1.51B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: WEST CONSHOHOCKEN, PA, United States
  • SEC registration: 801-116848 (status: Approved), registered 2019-06-27
  • Regulatory AUM (Form ADV): $5.80B as of 2026-08-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 1 hedge funds
  • Website: fairmountfunds.com

Portfolio Structure

  • 12 positions · $1.51B reported value (Q2 2026)
  • Top 10 holdings = 97.6% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 23.3%
  • Average position size: $126.08M

Sector Tilt

  • Health Care 96.2%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 added, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Fairmount Funds Management LLC appears to maintain a cautious stance with a focus on health care sector, indicating a belief in the potential growth within this industry. The quarter-over-quarter (QoQ) share count stability suggests a conservative approach to rebalancing. 2. Key Moves: - Added: Viridian Therapeutics Inc. (VRDN) with a significant increase of 30.1% in shares, indicating a strategic move into this company. - No Reductions: There were no reported reductions in holdings, suggesting a defensive strategy or a preference for maintaining current positions. - Hold: The majority of the holdings were held steady with no changes in share count, reflecting a conservative approach. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be more passive, with a high number of holdings held steady and no significant changes in share count. - Sector Bias: The fund has a strong bias towards the health care sector, with 10 out of 12 holdings in this sector. - Risk Appetite: The risk appetite is moderate, with a conservative approach to rebalancing and no aggressive additions or deletions. 4. Per-Holding One-Liner: - ORKA: ORKA Therapeutics Inc. (Health Care) - DNTH: Dianthus Therapeutics Inc. (Health Care) - DMRA: Damora Therapeutics Inc. (Health Care) - COGT: Cogent Biosciences Inc. (Health Care) - JBIO: Jade Biosciences Inc. (Health Care) - ELVN: Enlivene Therapeutics Inc. (Health Care) - VRDN: Viridian Therapeutics Inc. (Health Care) - Added, significant increase - ZBIO: Zenas Biopharma Inc. (Health Care) - CBIO: Crescent BioPharma Inc. (Health Care) - APGE: Apogee Therapeutics Inc. (Health Care) 5. One-Sentence Style Summary: Fairmount Funds Management LLC maintained a conservative stance in Q2 2026, focusing on health care sector investments with a strategic addition to Viridian Therapeutics Inc., reflecting a cautious yet sector-specific growth outlook.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 96.2%
Other 3.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.71M $352.63M 23.31%
23.31%
Hold
2 2.54M $247.33M 16.35%
16.35%
Hold
3 8.71M $226.63M 14.98%
14.98%
Hold
4 5.50M $212.98M 14.08%
14.08%
Hold
5 4.55M $101.18M 6.69%
6.69%
Hold
6 1.86M $94.17M 6.22%
6.22%
Hold
7 5.09M $93.52M 6.18%
6.18%
Add
8 2.36M $59.87M 3.96%
3.96%
Hold
9 2.75M $49.46M 3.27%
3.27%
Hold
10 298.65K $39.64M 2.62%
2.62%
Hold
11 722.02K $18.05M 1.19%
1.19%
New
12 8.62M $17.51M 1.16%
1.16%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 84% · recall 84% · F1 84% · avg rank error 2.3 · Top-10 turnover 17%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% AXSM · IMGN · NUVL · APGE · RYZB · KNSA · ARGX · ATXS · VRDN · ELVN AXSM · NUVL · APGE · DNTH · KNSA · ELVN · ATXS · VRDN · MRUS · COGT
2024-Q2 80% 80% 80% AXSM · NUVL · APGE · DNTH · KNSA · ELVN · ATXS · VRDN · COGT · MRUS AXSM · NUVL · SYRE · APGE · ELVN · DNTH · KNSA · COGT · ATXS · PTGX
2024-Q3 80% 80% 80% AXSM · NUVL · SYRE · ELVN · APGE · DNTH · KNSA · COGT · PTGX · ATXS AXSM · NUVL · APGE · SYRE · ELVN · KNSA · ORKA · VRDN · DNTH · COGT
2024-Q4 90% 90% 90% AXSM · NUVL · SYRE · APGE · VRDN · ELVN · KNSA · ORKA · DNTH · COGT AXSM · NUVL · SYRE · APGE · SRRK · ELVN · VRDN · ORKA · DNTH · COGT
2025-Q1 100% 100% 100% AXSM · NUVL · SYRE · APGE · SRRK · VRDN · ELVN · ORKA · DNTH · COGT AXSM · APGE · SYRE · ELVN · NUVL · DNTH · VRDN · SRRK · COGT · ORKA
2025-Q2 90% 90% 90% AXSM · APGE · SYRE · ELVN · DNTH · NUVL · VRDN · SRRK · COGT · ORKA APGE · AXSM · ELVN · SRRK · SYRE · NUVL · DNTH · KNSA · VRDN · COGT
2025-Q3 90% 90% 90% APGE · AXSM · ELVN · SRRK · SYRE · NUVL · DNTH · KNSA · VRDN · COGT DNTH · COGT · AXSM · APGE · ELVN · VRDN · ORKA · KNSA · SRRK · SYRE
2025-Q4 70% 70% 70% COGT · DNTH · AXSM · APGE · ELVN · VRDN · KNSA · ORKA · SRRK · SYRE COGT · APGE · SYRE · VRDN · ORKA · DNTH · ZBIO · NUVL · JBIO · ELVN
2026-Q1 80% 80% 80% COGT · APGE · SYRE · VRDN · ORKA · DNTH · ZBIO · JBIO · NUVL · ELVN DMRA · DNTH · COGT · SYRE · ORKA · VRDN · ELVN · JBIO · CBIO · ZBIO
2026-Q2 ★ 90% 90% 90% DMRA · DNTH · SYRE · COGT · ORKA · VRDN · ELVN · JBIO · CBIO · ZBIO ORKA · DNTH · DMRA · COGT · JBIO · ELVN · VRDN · ZBIO · CBIO · APGE

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Fairmount Funds Management LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Fairmount Funds Management LLC reported 12 equity positions worth $1.51B in aggregate; its largest disclosed positions were ORKA ($352.63M), DNTH ($247.33M), DMRA ($226.63M).

How large is Fairmount Funds Management LLC's portfolio?

Fairmount Funds Management LLC reported $1.51B of long equity holdings across 12 positions as of 2026-Q2. Top-10 holdings account for 97.6% of reported value.

What is Fairmount Funds Management LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/fairmount-funds-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →